Phil B.FontanarosaMD, Interim CoeditorIndividualAuthorMargaret A.WinkerMD, Deputy EditorIndividualAuthorStephenLurieMD PhD, Fishbein FellowIndividualAuthor
To the Editor: Dr Friedman and colleagues1 downplayed serious safety questions about dexfenfluramine,
mibefradil, and bromfenac sodium, which were approved in 1996-1997 and subsequently
removed from the market, that were raised prior to marketing. Furthermore,
Friedman et al failed to acknowledge that these drugs did not represent significant
advances over the numerous approved drugs in their therapeutic categories.
Lurie P, Sasich LD. Safety of FDA-Approved Drugs. JAMA. 1999;282(24):2297–2298. doi:10.1001/jama.282.24.2297
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: